Journal of Clinical Oncology

Vol. 43, Issue 16_suppl Issue 16_suppl 2025
6439
Articles

Articles in this Issue

A multicenter randomized phase II trial assessing the efficacy and safety of mCapOX plus cetuximab and mFOLFOX6 plus cetuximab as first-line treatment for patients with RAS/BRAF wild-type metastatic colorectal cancer: Primary results of the CAPCET study.

Yuwen Zhou, Ping Chen, Jin Wang et al. Jun 01, 2025 pp. 3563-3563 10.1200/jco.2025.43.16_suppl.3563

3563 Background: This CAPCET randomized phase II trial was designed to assess the efficacy and safety of modified capecitabine and oxaliplatin (mCapOX) pl...

The impact of dietary factors on esophageal cancer over three decades: A global epidemiological overview.

Aishwar Dixit, Sweta Sahu, Prerna Chandra et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16155

e16155 Background: Esophageal cancer remains a major global health concern due to its high mortality and disability burden. Dietary risk factors, such as...

Efficacy and safety of regorafenib combination with PD-1 inhibitors vs. regorafenib monotherapy in second-line treatment for patients with unresectable hepatocellular carcinoma after failure of different first-line treatments: A multicenter retrospective real-world study.

Weihong Ma, Jiamin Cheng, Hongli Yu et al. Jun 01, 2025 pp. 4088-4088 10.1200/jco.2025.43.16_suppl.4088

4088 Background: Regorafenib is the first oral targeted drug as a second-line agent in patients with unresectable hepatocellular carcinoma (HCC) who progr...

Validation of a study design that promotes diversity in clinical trials.

Lauren Jhon Lee, Victoria Poillucci, Mathew Lonberg Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e23000

e23000 Background: Diversity and inclusivity in clinical trials are important for generating well-balanced biomedical data for analysis. The ongoing, mult...

Impact of in vitro fertilization on malignant transformation of endometriotic cysts: A retrospective cohort analysis of endometriosis-associated ovarian cancers.

Yiwei Zhao, Taiyang Ye, Yang Zhou et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e17581

e17581 Background: Endometriosis, affecting 10% of reproductive-aged women, carries a 1–3% lifetime risk of malignant transformation, predominantly to cle...

Impact of a collaborative care-based symptom intervention model on chemotherapy adherence in patients with breast cancer.

Michael H. Storandt, Kathryn Jean Ruddy, Veronica Grzegorczyk et al. Jun 01, 2025 pp. 1543-1543 10.1200/jco.2025.43.16_suppl.1543

1543 Background: Treatment toxicity may limit the ability of cancer patients to receive all recommended cycles of therapy. Four to six cycles of docetaxel...

Improving infusion therapy management in metastatic breast cancer: Real-world pilot study of a new pharmacy resource.

Reshma L. Mahtani, Aditya Bardia, Sara M. Tolaney et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13115

e13115 Background: Infusion-based therapies are integral to the treatment of metastatic breast cancer. However, their management requires complex coordina...

Phase 1 study of the anti–immunoglobulin-like transcript 3 (ILT3) monoclonal antibody (mAb) MK-0482 + pembrolizumab (pembro) + paclitaxel for previously untreated advanced triple negative breast cancer (TNBC).

Seock-Ah Im, Carlos Rojas, Iván Victoria et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13135

e13135 Background: First-line treatment for advanced TNBC with PD-L1 CPS ≥10 is chemotherapy plus pembro. ILT3 is an inhibitory receptor expressed on mono...

Co-designing a smartphone-based navigation system for cancer patients.

Timothy William Mullett, Pamela Hull Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13727

e13727 Background: Kentucky ranks 1st among states for the worst overall cancer incidence and mortality in the U.S., with...

Conversion therapy for initially unresectable intrahepatic cholangiocarcinoma: A multicenter real-world study.

Xinhao Xiong, Wei Dai, Jinzhang Chen et al. Jun 01, 2025 pp. 4118-4118 10.1200/jco.2025.43.16_suppl.4118

4118 Background: Currently, studies on conversion therapy for intrahepatic cholangiocarcinoma (ICC) are relatively limited. Effectiveness and optimization...

Neoadjuvant chemoimmunotherapy with afatinib for locally advanced head and neck squamous cell carcinoma (neoCHANCE-2): An open-label, single-arm, phase 2 study.

Zhigong Wei, Huijiao Chen, Fei Chen et al. Jun 01, 2025 pp. 6069-6069 10.1200/jco.2025.43.16_suppl.6069

6069 Background: Neoadjuvant chemoimmunotherapy has been an emerging hotspot for the treatment of locally advanced head and neck squamous cell carcinoma (...

Gender disparities in major adverse cardiovascular and cerebrovascular events among liver cancer patients: A nationwide analysis (NIS 2016–2021).

Niti Chokshi, Sharan Jhaveri, Darshilkumar Maheta et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16271

e16271 Background: Liver cancer poses a major global health burden, with gender differences influencing outcomes & cardiovascular risks. This study ex...

Association of enrichment of CD7⁺CXCR3⁺ CAR T cells in infusion products with remission in relapsed or refractory diffuse large B-cell lymphoma.

Michel Obeid, Robin Bartolini, Lionel Trueb et al. Jun 01, 2025 pp. 7020-7020 10.1200/jco.2025.43.16_suppl.7020

7020 Background: Chimeric antigen receptor (CAR) T-cell therapy is the standard of care for relapsed or refractory diffuse large B-cell lymphoma (R/R DLBC...

Epidemiological analysis of gastric cancer in Uzbekistan.

Abbos Abdukodirov, Mirzagaleb Tillyashaykhov, Sayde Djanklich et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13673

e13673 Background: Gastric cancer (GC) represents a significant public health concern, ranking among the leading causes of morbidity and mortality globall...

Dosing decitabine and venetoclax for terminal differentiation to improve outcomes in TP53 mutant MDS and AML.

Bradley Rockwell, Ioannis Mantzaris, Aditi Shastri et al. Jun 01, 2025 pp. 6514-6514 10.1200/jco.2025.43.16_suppl.6514

6514 Background: Mutations in the tumor suppressor TP53 gene are common in elderly patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia...

Influence of pre-existing autoimmune disease on outcomes in patients treated with CD-19 targeting CAR-t cell therapy for lymphoma: A retrospective propensity score matched study utilizing TriNetX.

Shanawar Ali Waris, Nanda Siva, Adnan Saifuddin et al. Jun 01, 2025 pp. 7033-7033 10.1200/jco.2025.43.16_suppl.7033

7033 Background: There is a lack of studies in the literature about the impact of baseline autoimmune diseases (AD) on outcomes in patients with lymphoma...

A randomized, controlled pilot trial of a neuromodulatory digital therapeutic for individuals with breast cancer.

Samantha Adler, Brett Colbert, Mariya Petrova et al. Jun 01, 2025 pp. 1579-1579 10.1200/jco.2025.43.16_suppl.1579

1579 Background: Fatigue, pain, and mood symptoms are common side effects of cancer therapy and cancer patients. Frontoparietal circuitry has been implica...

NF1- and non-NF1–associated malignant peripheral nerve sheath tumors (MPNST): The University of Texas MD Anderson (MDACC) experience.

Reeja Raj, Reshma Vilson, Cissimol Joseph et al. Jun 01, 2025 pp. 11576-11576 10.1200/jco.2025.43.16_suppl.11576

11576 Background: MPNSTs are aggressive sarcomas with poor prognosis due to their high propensity for metastasis, rapid growth and limited response to sta...

De-escalation of axillary surgery in breast cancer patients with 1-2 positive sentinel nodes after neoadjuvant systemic therapy.

Jinyoung Byeon, Eunhye Kang, Ji-Jung Jung et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e12612

e12612 Background: Axillary lymph node dissection (ALND) is the standard treatment for patients with tumor-positive sentinel nodes after neoadjuvant syste...

Change in practice patterns over time for endocrine therapy (ET) and radiation therapy (RT) in women with breast cancer age 65 and older.

Aubrey Stickland, Xueting Tao, Kelley M. Kidwell et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e12574

e12574 Background: In 2016, the American College of Surgeons (ACS) recommended omitting RT for women over age 70 with stage 1, HR+ breast cancer after lum...

Effectiveness of alternating magnetic field therapy on quality of life among cancer survivors with chemotherapy-induced peripheral neuropathy: Insights of SMILE study.

Emi Kubo, Eriko Satomi, Toru Mukohara et al. Jun 01, 2025 pp. 12034-12034 10.1200/jco.2025.43.16_suppl.12034

12034 Background: Chemotherapy-induced peripheral neuropathy (CIPN) reduces patients' quality of life (QoL) due to consistent sensory and motor disturbanc...

Circulating tumor DNA concentrations and blood tumor mutation burden as biomarkers of outcomes in a phase 1 study of select advanced solid tumors.

Jin Lu, Jason Howe, Sadhna Shankar et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e14550

e14550 Background: Circulating tumor DNA (ctDNA) and tumor mutation burden (TMB) have demonstrated value as biomarkers of response in oncology clinical tr...

Re-evaluation of HER2 status and prognostic implications of ultra-low and low HER2 expression in estrogen receptor–positive breast cancer.

Young-Jin Lee, Sae Byul Lee, Hee Jin Lee et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e12546

e12546 Background: Recent studies have shown antibody-drug conjugates' efficacy in HER2-low breast cancer, but the classification and clinical significanc...

ctDNA-guided adjuvant radiation for patients with HPV-related oropharyngeal cancer: First planned interim analysis of a phase II multisite study.

James Edward Bates, William A. Stokes, Jill Remick et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e18080

e18080 Background: Patients with early-stage HPV-related oropharyngeal squamous cell carcinoma (HPV-OPSCC) have favorable outcomes when treated with trans...

Augmenting clinician workflow to enable delivery of guideline concordant cancer care with an LLM-based system.

Divneet Mandair, Travis Zack, Allison W. Kurian et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13702

e13702 Background: Applying Large Language Models (LLMs) to multifactorial data for patients with cancer may facilitate guideline-concordant care delivery...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page